Andalusia has received the first 10,000 doses of the Novavax laboratory’s Nuvaxovid vaccine. This protein-based vaccine, a different technology to the preparations that have been inoculated since the start of the campaign, is indicated for people over 18 years of age who have not been able to start or complete vaccination, either because of severe adverse reactions to mRNA vaccines, a history of allergy to any of their components or other medical indications that recommend avoiding the administration of mRNA vaccines. In addition, it will be offered to people who have declined vaccination with the previously available vaccines.
Nuvaxovid contains a laboratory-produced version of a protein found on the surface of SARS-CoV-2 (the spicule protein) and an adjuvant, a substance that helps boost the immune response. When this vaccine is administered, the immune system identifies the protein as foreign and naturally produces defences – antibodies and T-cells – against the virus. If the vaccinated person later comes into contact with the disease, their immune system will recognise the virus protein and be prepared to deal with it. Antibodies and immune cells can protect against Covid-19 by working together to kill the virus, preventing it from entering the body’s cells and destroying infected cells.
Andalusia thus currently maintains vaccination with the mRNA, Moderna and Pfizer preparations for the general population and the Pfizer children’s version for children under 12 years of age. In total, the community has already received more than 18 million doses since the start of the campaign in December 2020.